The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
NCT05092802 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2022-05-03
Summary
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation
Conditions
- Brain Tumor, Primary
Interventions
- DRUG
-
HLX208
450mg bid po
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Jinming Yu · Shandong Cancer Hospital and Institute
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-23
- Primary Completion
- 2023-05-30
- Completion
- 2024-05-30
Countries
- China
Study Locations
More Related Trials
-
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
NCT06780930 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
HMPL-813 in Treating Patients With Glioblastoma
NCT03231501 ·Status: UNKNOWN ·Phase: PHASE1
-
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
NCT01986348 ·Status: TERMINATED ·Phase: PHASE2
-
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
NCT04197492 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas
NCT05473923 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
NCT06072586 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
NCT02626364 ·Status: COMPLETED ·Phase: PHASE2
-
Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL
NCT05054426 ·Status: UNKNOWN ·Phase: PHASE3
-
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
NCT07025018 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
NCT04762069 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
NCT07093814 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
NCT00797940 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
NCT01349036 ·Status: TERMINATED ·Phase: PHASE2
-
Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
NCT04915404 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
NCT05376800 ·Status: COMPLETED ·Phase: PHASE1
-
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
NCT00704288 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
NCT04421378 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
NCT07286292 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
NCT00052013 ·Status: COMPLETED ·Phase: PHASE2
-
Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
NCT02848794 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
NCT06852001 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
NCT00006119 ·Status: COMPLETED ·Phase: PHASE2
-
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
NCT05868083 ·Status: UNKNOWN ·Phase: PHASE1
-
AMG 595 First-in-Human in Recurrent Gliomas
NCT01475006 ·Status: COMPLETED ·Phase: PHASE1